Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vibha Ravi

Advertisement
Set Alert for Articles By Vibha Ravi

Latest From Vibha Ravi

India's USV Reveals Investment Plans

Indian firm USV plans to spend $56.4m on a new drug formulations unit in Vadodara and $11.3m to upgrade its existing API unit near Mumbai as it eyes expanded capacity and additional sales in Europe.

Manufacturing Strategy

India's USV Plans Manufacturing Investments, New Formulations Unit To Target Europe

Indian firm USV plans to spend $56.4m on a new drug formulations unit in Vadodara and $11.3m to upgrade its existing API unit near Mumbai as it eyes expanded capacity and additional sales in Europe.

Commercial Manufacturing

Strides Plans Re-Entry On Injectables

Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.

Commercial Strategy

Strides Plans Injectables Re-entry As Mylan Non-Compete Nears End

Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.  

Commercial Strategy

Facing Regulatory Heat, Indian Pharma Turns To Quality Solutions

Against a backdrop of US FDA warnings and global regulatory convergence, the Indian pharma industry is looking to build in quality from project inception and foster an unbiased approach to quality across global markets, a conference in Mumbai hears.

 

India Quality

Stempeutics Eyes Global Markets For New Crohn's Symptom Cell Therapy

Stempeutics explores stem cell therapy in India for Crohn’s disease-related perianal fistulae while considering entry into other Asian markets.

Research & Development India
See All
Advertisement
UsernamePublicRestriction

Register